A prospective observational study evaluating intestinal microbiome as a biomarker to predict the efficacy and toxicity of prostate cancer patients receiveing PARP inhibitors alone or combined with novel ADT agents
Ontology highlight
ABSTRACT: Interventions: case series:None
Primary outcome(s): side effects
Study Design: Sequential
DISEASE(S): Prostate Cancer
PROVIDER: 2707329 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA